Shandong Company Profile
✉ Email this page to a colleague
What is the competitive landscape for SHANDONG
SHANDONG has sixteen approved drugs.
There are five US patents protecting SHANDONG drugs. There are two tentative approvals on SHANDONG drugs.
There are twenty-nine patent family members on SHANDONG drugs in fourteen countries and fifty-four supplementary protection certificates in thirteen countries.
Summary for Shandong
| International Patents: | 29 |
| US Patents: | 5 |
| Tradenames: | 14 |
| Ingredients: | 14 |
| NDAs: | 16 |
Drugs and US Patents for Shandong
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shandong Luye | RYKINDO | risperidone | FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 212849-002 | Jan 13, 2023 | RX | Yes | Yes | 9,446,135 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Shandong | OSELTAMIVIR PHOSPHATE | oseltamivir phosphate | CAPSULE;ORAL | 217274-003 | Jul 9, 2025 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Shandong Luye | RYKINDO | risperidone | FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 212849-003 | Jan 13, 2023 | RX | Yes | No | 9,446,135 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Shandong | ROSUVASTATIN CALCIUM | rosuvastatin calcium | TABLET;ORAL | 207375-004 | May 7, 2019 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Shandong Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Korea | 101539313 | ⤷ Start Trial |
| Brazil | 112013027235 | ⤷ Start Trial |
| Poland | 3199146 | ⤷ Start Trial |
| Spain | 2607497 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Shandong Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2101777 | 300813 | Netherlands | ⤷ Start Trial | PRODUCT NAME: AMBRISENTAN TOEGEPAST IN COMBINATIEBEHANDELING MET TADALAFIL; REGISTRATION NO/DATE: EU/1/08/451 (C(2008) 1637) 20151125 |
| 0247633 | 97C0103 | Belgium | ⤷ Start Trial | PRODUCT NAME: CALCII ATORVASTATINUM TRIHYDRICUM (=ATORVASTATINUM); NAT. REGISTRATION NO/DATE: 19 IS 95 F 3 19970922; FIRST REGISTRATION: GB PL/00018/0240 19961107 |
| 0720599 | 300688 | Netherlands | ⤷ Start Trial | PRODUCT NAME: EZETIMIBE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, EN ROSUVASTATINE; NATIONAL REGISTRATION NO/DATE: RVG114002-004 20140811; FIRST REGISTRATION: NO 13-9663 - 9665 20140724 |
| 0720599 | 92544 | Luxembourg | ⤷ Start Trial | PRODUCT NAME: EZETIMIBE EN COMBINAISON AVEC ROSUVASTATINE OU LEURS SELS PHARMACEUTIQUEMENT ACCEPTEES, Y COMPRIS ROSUVASTATINE SOUD FORME DE SEL DE ZINC; FIRST REGISTRATION DATE: 20140724 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
